文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

作者信息

He Kewen, Puebla-Osorio Nahum, Barsoumian Hampartsoum B, Sezen Duygu, Rafq Zahid, Riad Thomas S, Hu Yun, Huang Ailing, Voss Tifany A, Kettlun Leyton Claudia S, Schuda Lily Jae, Hsu Ethan, Heiber Joshua, Cortez Maria-Angelica, Welsh James W

机构信息

Department of Radiation Oncology, Shandong First Medical University and Shandong Academy of Medical Sciences, Shandong Cancer Hospital and Institute, Jinan, Shandong, China.

Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

J Exp Clin Cancer Res. 2024 Sep 10;43(1):256. doi: 10.1186/s13046-024-03183-9.

DOI:10.1186/s13046-024-03183-9
PMID:39256857
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11386066/
Abstract
摘要

相似文献

[1]
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

J Exp Clin Cancer Res. 2024-9-10

[2]
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

J Exp Clin Cancer Res. 2024-9-2

[3]
Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.

J Pharmacol Exp Ther. 2021-11

[4]
ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer.

Future Oncol. 2023-7

[5]
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer.

J Immunother Cancer. 2022-9

[6]
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.

J Virol. 2020-1-17

[7]
Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.

J Immunother Cancer. 2024-4-11

[8]
Linear IgA bullous dermatosis induced by nemvaleukin alfa, an engineered interleukin 2 molecule, in a patient with treatment-refractory metastatic melanoma.

JAAD Case Rep. 2023-9-14

[9]
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Oncoimmunology. 2018-2-14

[10]
Reprogramming Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti-PD1 Therapy.

bioRxiv. 2023-1-27

本文引用的文献

[1]
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.

J Exp Clin Cancer Res. 2024-9-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索